StockData
Outlook Therapeutics, Inc. logo

Outlook Therapeutics, Inc. (OTLK) stock

OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 18, 2026Score 4/30
$0.36−0.04 (-8.94%)

Close on Nov 17, 2026Market cap $87.79MP/E –Yield –

Outlook Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

No ev/ebitda figures for Outlook Therapeutics

Outlook Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Outlook Therapeutics figures

See a number that looks wrong?